Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;18(6):1119-1127.
doi: 10.1002/alz.12441. Epub 2021 Jul 26.

Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project

Mercè Boada  1   2 , Adrián Rodrigo  3 , Frank Jessen  4   5 , Bengt Wimblad  6   7 , Milica G Kramberger  8 , Pieter Jelle Visser  9   10 , Rafael Simó  11   12 , Octavio Rodríguez-Gomez  1 , Andreea Ciudin  11   12 , Jean Georges  13 , Annete Dumas  14 , Peggy Maguire  15 , David Krivec  16 , Anders Wimo  6 , Sergi Valero  1   2 , Montserrat Alegret  1   2 , Laura Jamilis  3 , Marissa Zwan  9 , Lena Sannemann  4 , Jordi Arrufat  17 , Erik Stomrud  18   19 , Gunilla Johansson  6 , Craig Shering  20 , Bridget Glaysher  21 , Neil Stewart  21 , Mark Belger  22 , Fatima Iradier  23 , Laura Campo  24 ; MOPEAD consortium
Affiliations

Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project

Mercè Boada et al. Alzheimers Dement. 2022 Jun.

Abstract

Introduction: The Models of Patient Engagement for Alzheimer's Disease (MOPEAD) project was conceived to explore innovative complementary strategies to uncover hidden prodromal and mild Alzheimer's disease (AD) dementia cases and to raise awareness both in the general public and among health professionals about the importance of early diagnosis.

Methods: Four different strategies or RUNs were used: (a) a web-based (WB) prescreening tool, (2) an open house initiative (OHI), (3) a primary care-based protocol for early detection of cognitive decline (PC), and (4) a tertiary care-based pre-screening at diabetologist clinics (DC).

Results: A total of 1129 patients at high risk of having prodromal AD or dementia were identified of 2847 pre-screened individuals (39.7%). The corresponding proportion for the different initiatives were 36.8% (WB), 35.6% (OHI), 44.4% (PC), and 58.3% (DC).

Conclusion: These four complementary pre-screening strategies were useful for identifying individuals at high risk of having prodromal or mild AD.

Keywords: Alzheimer's disease; diagnostic gap; early diagnosis; patient engagement; population-based screening.

PubMed Disclaimer

Conflict of interest statement

Laura Campo a full‐time employee of Eli Lilly Italia S.p.A. and shareholder of Eli Lilly. Frank Jessen has received consulting fees from Abbvie, AC‐Immune, Biogen, Danone/Nutricia, Eisai, Green Valley, Grifols, Janssen, MSD, Roche, and Vifor and has participated in advisory boards for AC Immune. Bengt Wimblad has participated in advisory boards for Alzinova, Axon Neuroscience, Biogen, and Resverlogix. Mercè Boada has received consulting fees from Biogen, Roche, and Merck. Fundació ACE has received funding from Grifols, Cortexmy, Abbvie, and Zambon. Peggy Maguire has received honoraria from University of Lodz (Poland). Anders Wimo has received funding/consulting fees from Eli Lilly, MSD, Eisai/Pfizer, Biogen, and Gates Ventures. Pieter Jelle Visser has received research grants from ZonMW, IMI, and Biogen and consulting fees from Synapsis. Rafael Simó has received research grants from Novo Nordisk, Roche, OM pharma, Abbott, Air liquid, and Lilly. Craig Shering is an AstraZeneca employee and receives AstraZeneca stock as part of his remuneration. All other authors report no conflict of interests.

References

    1. Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15(5):455‐532. - PubMed
    1. Bruandet A, Richard F, Bombois S, et al. Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(2):133‐139. - PubMed
    1. Leifer BP. Early diagnosis of Alzheimer's disease: clinical and economic benefits. J Am Geriatr Soc. 2003;51(5s2):S281‐S288. - PubMed
    1. Rodríguez‐Gómez O, Rodrigo A, Iradier F, et al. The MOPEAD project: advancing patient engagement for the detection of “hidden” undiagnosed cases of Alzheimer's disease in the community. Alzheimer's Dement. 2019;15(6):828‐839. - PubMed
    1. Rodrigo A, Trigueros P, Jamilis L, et al. Identification of undiagnosed dementia cases using a web‐based pre‐screening tool: the MOPEAD project. Alzheimer's Dement. 2021;17(8):1307‐1316. - PMC - PubMed

Publication types